TSX News -
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting
TORONTO, ONTARIO–(Marketwired – May 18, 2016) – Trillium Therapeutics Inc. (TSX:TR) (NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies […]